Among patients with chronic obstructive pulmonary disease who received prior treatment with multiple-inhaler triple therapy, single-inhaler triple therapy was effective in improving health status and ...

Selecting appropriate inhalers based on individual characteristics and shared decision-making is crucial for optimizing care for patients with COPD. Jeffrey D. Dunn ...

Please provide your email address to receive an email when new articles are posted on . The single inhaler combined budesonide, glycopyrrolate and formoterol fumarate. The risk for cardiopulmonary ...

Please provide your email address to receive an email when new articles are posted on . Compared with a dual therapy inhaler, a triple therapy inhaler improved inspiratory capacity in those with COPD.

The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with the ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Two posters presented at the CHEST Annual Meeting 2023 showed how real-world exacerbation rates in asthma and chronic obstructive pulmonary disease (COPD) dropped after patients started using a single ...

(HealthDay News) — For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled ...

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation. William B. Feldman, MD, MPH, from ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...